Siegfried Holding AG Stock OTC Markets

Equities

SGFEF

CH0014284498

Pharmaceuticals

Delayed OTC Markets 14:13:53 2024-05-30 EDT 5-day change 1st Jan Change
965 USD -3.60% Intraday chart for Siegfried Holding AG -3.60% +14.07%

Financials

Sales 2024 * 1.3B 1.46B 2B Sales 2025 * 1.42B 1.59B 2.17B Capitalization 3.81B 4.28B 5.85B
Net income 2024 * 148M 166M 227M Net income 2025 * 172M 193M 264M EV / Sales 2024 * 3.2 x
Net Debt 2024 * 351M 394M 538M Net Debt 2025 * 313M 352M 481M EV / Sales 2025 * 2.91 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
22.1 x
Employees 3,945
Yield 2024 *
0.43%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.60%
1 week-3.60%
1 month-3.60%
3 months-3.60%
6 months+14.07%
Current year+14.07%
More quotes
1 week
965.00
Extreme 965
965.00
1 month
965.00
Extreme 965
965.00
Current year
965.00
Extreme 965
1 001.00
1 year
837.50
Extreme 837.5
1 001.00
3 years
685.00
Extreme 685
1 001.00
5 years
459.00
Extreme 459
1 001.00
10 years
159.64
Extreme 159.6368
1 001.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-04-30
Chief Tech/Sci/R&D Officer 56 19-03-31
Corporate Officer/Principal - 14-01-31
Members of the board TitleAgeSince
Director/Board Member 55 15-12-31
Director/Board Member 63 13-12-31
Chairman 61 09-12-31
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, May 30, 2024 at 02:13 pm

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
889 CHF
Average target price
1,016 CHF
Spread / Average Target
+14.27%
Consensus